



CHULABHORN
ROYAL ACADEMY

Princess Srisavangavadhana Faculty of Medicine

2nd ANNUAL AGILE^{DxRx} CONFERENCE

Alliance for Global Implementation of Lung and Cardiac
Early Disease Detection and Treatment



47th International Conference
on Screening for Lung Cancer

&

15th Conference on Early Lung
Cancer Research on Treatment

Hosted by the **Princess Srisavangavadhana Faculty of Medicine,
Chulabhorn Royal Academy**

April 3 - 5, 2025

**Okura Prestige Hotel
Bangkok, Thailand**

NO FEES, HYBRID EVENT



SCAN & REGISTER



Organized by the Early Diagnosis and Treatment Research Foundation and
the iDNA (Institute for Diagnostic Accuracy)



Mission Statement

The early detection of lung cancer using thoracic CT has been widely demonstrated in multiple international trials to objectively increase cure rates. Now the international focus is on effective and economical implementation. Increasingly, it is emerging that thoracic CT screening is also detecting a range of early tobacco-related diseases including cardiovascular disease and chronic obstructive pulmonary disease. These three diseases comprise the 'BIG3', as they collectively account for close to half of the premature deaths globally. Thoracic CT screening presents a unique opportunity to integrate care for this high risk cohort with a single imaging examination. We plan to develop optimized protocols for evaluation of these major diseases, explore challenges and define solutions in enabling implementation, especially for economically disadvantaged countries across the world. A core strategy in achieving this ambitious goal is to leverage the use of AI processes across the continuum of care, including its use for risk assessment, disease detection and managing disease interventions.

Planning Committee

Claudia Henschke, PhD, MD

Icahn School of Medicine at Mount Sinai
New York, NY

Matthijs Oudkerk, MD, PhD

University of Groningen
Groningen, Netherlands

David Yankelevitz, MD

Icahn School of Medicine at Mount Sinai
New York, NY

James Mulshine, MD

Rush University
Chicago, IL

John Field, MA, PhD, BDS, FRCPath

University of Liverpool
Liverpool, United Kingdom

Mario Silva, MD, PhD

University of Parma
Parma, Italy

Nattaya Triphuridet, MD, PhD

Princess Srisavangavadhana Faculty of Medicine
Bangkok, Thailand

Thursday, April 3, 2025

| | | |
|--------------------|---|---|
| 08:30–09:00 | Introduction to Sessions Welcome Address Research Updates Meeting Format | N Triphuridet, Y Sittichanbuncha C Henschke, M Oudkerk D Yankelevitz |
| 09:00–09:30 | Introductory Lecture: Global Implementation of National Lung Cancer Screening Programs: Key Considerations | C Henschke, M Oudkerk |
| 09:30–10:45 | Session 1: Understanding Disease Burden and Screening in Asia: Established Programs and Initiatives Moderators: HH Chen, PC Yang <ul style="list-style-type: none">• Tobacco• Overview of Lung Cancer Burden in Asia• Air Pollution• Occupational Exposure• Heart Disease• Emphysema• Never Smokers | C Heulton N Triphuridet H Kan S Markowitz Y Wang SM Lee PC Yang |
| 10:45–11:15 | Coffee Break | |
| 11:15–12:00 | Session 2: Panel Discussion on AGILE Mission Moderators: M Oudkerk, D Yankelevitz Panelists: S Asiamah, K Kelly, L Seijo, J Vogel-Claussen, Y Wang, PC Yang | |
| 12:00–12:50 | Session 3: Diagnostic and Therapeutic Technology Updates Moderators: S Fain, K Lau <ul style="list-style-type: none">• Hardware Updates• Endobronchial Directed Innovations• AI Applications | |
| 12:50–13:15 | Session 3: Roundtable | |
| 13:15–14:15 | Lunch Break | |
| 14:15–15:15 | Session 4: Role of Chest X-rays Moderators: C Henschke, R Smith <ul style="list-style-type: none">• Considerations for Screening: Review the Evidence• Potential for Improvement with AI• Tomosynthesis• Integration into a CT Screening Program | R Yip S Zheng N Triphuridet R Huber |
| 15:15–16:00 | Session 4: Panel Discussion Panelists: H de Koning, R Huber, J Vogel-Claussen, D Yankelevitz | |
| 16:00–16:45 | Marilyn and Jim Simons Keynote Lecture Introduction: C Henschke Integrating AI into the Screening Process | M Oudkerk |
| 16:45–17:00 | Coffee Break | |
| 17:00–17:45 | Session 5: Diagnostic Case Review Moderators: D Shaham, M Silva Panelists: S Asiamah, J Gratama, E Kazerooni, SM Lee, J Vogel-Claussen | |

Friday, April 4, 2025

| | | |
|--------------------|---|---|
| 08:30–09:45 | Session 6: Integrated Screening Moderators: J Mulshine, D Yankelevitz <ul style="list-style-type: none">• Combined Protocols• Updates on ROBINSCA• Updates on Emphysema• Role of Calibration• Additional findings (Osteoporosis, Liver, etc.) | A Walstra M Oudkerk S Fain R Avila J Vogel-Claussen |
| 09:45–10:30 | Session 6: Panel Discussion on Comorbidities Panelists: S Fain, E Kazerooni, SM Lee, A Stillman, J Vogel-Claussen, Y Wang | |
| 10:30–10:45 | Coffee Break | |
| 10:45–11:45 | Session 7: CT Protocol Updates Moderators: C Henschke, J Vogel-Claussen <ul style="list-style-type: none">• Impact of Time Delays• Defining the Benefits of Volumetry• Review of Two-Year Intervals• Significance of Solid Components in Lung Nodules | R Yip M Silva H de Koning H Lancaster |
| 11:45–12:30 | Session 7: Panel Discussion (Critical Issues) Panelists: R Avila, B Pyenson, SM Lee, M Silva, J Vogel-Claussen, A Walstra | |
| 12:30–13:30 | Lunch Break | |
| 13:30–14:30 | Session 8: Biomarkers: Usefulness and Integration Moderators: J Field, F Hirsch <ul style="list-style-type: none">• Summary of Their Uses in the Context of Screening: How Good Are They Now? (Image- and Blood-based)• How Good Do They Have to Be to Make Them Useful?• Methodology for Evaluation of Clinical Usefulness | H Robbins C Amos V Liebenberg |
| 14:30–15:15 | Session 8: Panel Discussion Moderators: J Field, J Mulshine Panelists: V Liebenberg, H Robbins, E Taioli, Y Yatabe | |
| 15:15–15:30 | Coffee Break | |
| 15:30–16:15 | Session 9: Incidental Nodules and Multifocal nodules Moderators: L Seijo, M Silva <ul style="list-style-type: none">• Extent of Problem and Potential Benefit• Program Implementation• Management Protocols• Multifocal Nodules | N Piyavisetpat R Osarogiagbon C van der Aalst C Aigner |
| 16:15–17:00 | Session 9: Panel Discussion Panelists: C Aigner, E Kazerooni, R Osarogiagbon, N Piyavisetpat, C van der Aalst | |

Saturday, April 5, 2025

| | | |
|--------------------|---|--|
| 09:00–10:00 | Session 10: Therapeutics Updates Moderators: M Infante, P Thongcharoen <ul style="list-style-type: none">• Surgery• Ablation• Immunotherapy• Radiation Therapy | HQ Chen K Lau K Kelly J Setakornnukul |
| 10:00–11:00 | Session 11: Therapeutic Case Review Moderators: C Aigner, D Yankelevitz Panelists: HQ Chen, M Infante, K Lau, M Heuvelmans, P Thongcharoen | |
| 11:00–11:30 | Coffee Break | |
| 11:30–12:30 | Session 12: Collaborations Towards Changing the Staging System for Early Stage Disease Moderators: J Mulshine, R Osarogiagbon <ul style="list-style-type: none">• IASLC• New Insights<ul style="list-style-type: none">◦ Radiology Perspective◦ Surgical Perspective◦ Medical Oncology Perspective◦ Pathology Perspective◦ Biomarker Consortiums | K Kelly C Henschke M Infante L Gros Y Yatabe H Robbins |
| 12:30–13:30 | Lunch Break | |
| 13:30–14:15 | Session 13: Advocacy in Asia and the Potential to Collaborate Moderator: C Heaton <ul style="list-style-type: none">• The Thailand Tobacco Control Experience• The Philippines Tobacco Control Experience• Creating Tobacco Free Generations | P Vathesatogkit U Dorotheo H Koong |
| 14:15–15:00 | Session 14: AGILE Position Papers <ul style="list-style-type: none">• Screening & Nodule Management Protocols• Methodological Considerations of AI Implementation• Integrating Emphysema Screening• Integrating Cardiovascular Screening• Methodological Considerations for Expanding Eligibility• International Collaborations for Screening Equity | C van der Aalst, D Yankelevitz K Myers, A Walstra S Fain, M Heuvelmans M Oudkerk, A Stillman S Markowitz, E Taioli J Field, R Smith |
| 15:00–15:15 | Closing Statements and Future Meetings | C Henschke, M Oudkerk |